NCT03357380View on ClinicalTrials.gov

A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver

PHASE1CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

November 28, 2017

Primary Completion Date

March 20, 2020

Study Completion Date

March 20, 2020

Conditions
Hepatobiliary DisordersNon-alcoholic Fatty Liver Disease
Interventions
DRUG

Semaglutide

Subcutaneously (under the skin) once-daily. Will be increased more or less every 4 weeks. It is expected that from week 16 until week 72 The participants take the maximum planned dose (0.4 mg) of study medicine.

DRUG

Placebo

Subcutaneously (under the skin) once-daily. Will be increased more or less every 4 weeks. It is expected that from week 16 until week 72 The participants take the maximum planned dose (0.4 mg) of study medicine.

Trial Locations (2)

41460

Novo Nordisk Investigational Site, Neuss

55116

Novo Nordisk Investigational Site, Mainz

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY